GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Gongwin Biopharm Holdings Co Ltd (ROCO:6617) » Definitions » PB Ratio

Gongwin Biopharm Holdings Co (ROCO:6617) PB Ratio : 3.35 (As of Apr. 17, 2025)


View and export this data going back to 2017. Start your Free Trial

What is Gongwin Biopharm Holdings Co PB Ratio?

The PB Ratio, or Price-to-Book ratio, or Price/Book, is a financial ratio used to compare a company's market price to its Book Value per Share. As of today (2025-04-17), Gongwin Biopharm Holdings Co's share price is NT$82.60. Gongwin Biopharm Holdings Co's Book Value per Share for the quarter that ended in Dec. 2024 was NT$24.64. Hence, Gongwin Biopharm Holdings Co's PB Ratio of today is 3.35.

Good Sign:

Gongwin Biopharm Holdings Co Ltd stock PB Ratio (=3.14) is close to 3-year low of 3.14.

The historical rank and industry rank for Gongwin Biopharm Holdings Co's PB Ratio or its related term are showing as below:

ROCO:6617' s PB Ratio Range Over the Past 10 Years
Min: 3.1   Med: 14.85   Max: 25.76
Current: 3.34

During the past 12 years, Gongwin Biopharm Holdings Co's highest PB Ratio was 25.76. The lowest was 3.10. And the median was 14.85.

ROCO:6617's PB Ratio is ranked worse than
63.47% of 1284 companies
in the Biotechnology industry
Industry Median: 2.08 vs ROCO:6617: 3.34

During the past 12 months, Gongwin Biopharm Holdings Co's average Book Value Per Share Growth Rate was 112.30% per year. During the past 3 years, the average Book Value Per Share Growth Rate was 41.30% per year. During the past 5 years, the average Book Value Per Share Growth Rate was 24.60% per year. During the past 10 years, the average Book Value Per Share Growth Rate was 41.20% per year.

During the past 12 years, the highest 3-Year average Book Value Per Share Growth Rate of Gongwin Biopharm Holdings Co was 389.10% per year. The lowest was -2.40% per year. And the median was 22.50% per year.

Back to Basics: PB Ratio


Gongwin Biopharm Holdings Co PB Ratio Historical Data

The historical data trend for Gongwin Biopharm Holdings Co's PB Ratio can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Gongwin Biopharm Holdings Co PB Ratio Chart

Gongwin Biopharm Holdings Co Annual Data
Trend Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24
PB Ratio
Get a 7-Day Free Trial Premium Member Only Premium Member Only 24.09 31.76 25.31 15.46 4.61

Gongwin Biopharm Holdings Co Quarterly Data
Dec17 Jun18 Dec18 Jun19 Dec19 Jun20 Dec20 Jun21 Dec21 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24
PB Ratio Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 15.46 16.36 5.65 4.68 4.61

Competitive Comparison of Gongwin Biopharm Holdings Co's PB Ratio

For the Biotechnology subindustry, Gongwin Biopharm Holdings Co's PB Ratio, along with its competitors' market caps and PB Ratio data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Gongwin Biopharm Holdings Co's PB Ratio Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Gongwin Biopharm Holdings Co's PB Ratio distribution charts can be found below:

* The bar in red indicates where Gongwin Biopharm Holdings Co's PB Ratio falls into.


;
;

Gongwin Biopharm Holdings Co PB Ratio Calculation

The PB Ratio, or Price-to-Book ratio, or Price/Book, is a financial ratio used to compare a company's market price to its Book Value per Share. It is a ratio widely used to value stocks.

Gongwin Biopharm Holdings Co's PB Ratio for today is calculated as follows:

PB Ratio=Share Price/Book Value per Share (Q: Dec. 2024)
=82.60/24.644
=3.35

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

It can also be calculated from the numbers for the whole company:

A closely related ratio is called Price-to-Tangible-Book. The difference between Price-to-Tangible-Book and PB Ratio is that book value other than intangibles are used in the calculation.


Gongwin Biopharm Holdings Co  (ROCO:6617) PB Ratio Explanation

Unlike valuation ratios relative to the earning power such as PE Ratio, PE Ratio without NRI, PS Ratio, Price-to-Operating-Cash-Flow , or Price-to-Free-Cash-Flow, the PB Ratio measures the valuation of the stock relative to the underlying asset of the company.

The PB Ratio works the best for the businesses that earn most of their profit from their assets, e.g. banks and insurance companies.


Be Aware

Some businesses have very light assets, such as software companies or insurance agencies. The PB Ratio does not work well for these companies. Some companies even have negative equity, so the PB Ratio cannot be applied to them.


Gongwin Biopharm Holdings Co PB Ratio Related Terms

Thank you for viewing the detailed overview of Gongwin Biopharm Holdings Co's PB Ratio provided by GuruFocus.com. Please click on the following links to see related term pages.


Gongwin Biopharm Holdings Co Business Description

Traded in Other Exchanges
N/A
Address
3rd Floor, No.80, Jianguo North Road, Section 1, Zongshan District, Taipei, TWN, 10491
Gongwin Biopharm Holdings Co Ltd is a Taiwanese biotech and pharmaceutical company engaged in research and development of anti-cancer drugs. The company develops products related to central lung serious tracheal obstruction, primary liver cancer, malignant pleural effusion, and tracheal adenoid cystic carcinoma.

Gongwin Biopharm Holdings Co Headlines

No Headlines